4.2 Article

Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons

Journal

DIGESTIVE DISEASES
Volume 33, Issue -, Pages 105-112

Publisher

KARGER
DOI: 10.1159/000437104

Keywords

Inflammatory bowel disease; Microbiota; Antibiotics; Probiotics; Fecal transplantation; Prebiotics

Funding

  1. Abbvie
  2. Biocodex
  3. Danone
  4. Hospira
  5. Merck medication familiale
  6. MSD
  7. Nestle

Ask authors/readers for more resources

Microorganisms present in the intestine possess proinflammatory or anti-inflammatory activities which may modulate inflammatory bowel disease (IBD). The concepts followed by researchers in trying to target the microbiota in IBD were to decrease pathogens or pathobionts, or only the microbial load, and more recently, to favor growth and persistence of favorable microorganisms. We review, here, those concepts and critically analyze the clinical data (especially randomized controlled trials) obtained using antibiotics and probiotics. We eventually present and criticize the rational and data obtained so far following new research strategies including the use of new probiotics, genetically modified organisms and fecal transplantation. (C) 2015 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available